{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:39:12Z","timestamp":1791290352967,"version":"4.3.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005845","name":"Hyogo College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005845","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The role of recurrence-free survival (RFS) as a valid surrogate endpoint for overall survival (OS) in patients who underwent upfront surgery for colorectal liver metastases remains uncertain. The aim of the study was to compare the two survival measures in a nationwide cohort of upfront resected colorectal liver metastasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from patients with colorectal liver metastases without extrahepatic metastases who underwent curative surgery for liver metastases were retrieved from the Japanese nationwide database (data collection 2005\u20132007 and 2013\u20132014). RFS, OS, and survival after recurrence were estimated using the Kaplan\u2013Meier method. The correlation (\u03c1) between RFS and OS was assessed using the rank correlation method combined with iterative multiple imputation, to account for censoring. As a secondary analysis, the correlation was evaluated according to adjuvant chemotherapy regimen. In sensitivity analysis, the pairwise correlation between RFS and OS was calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 2385 patients with colorectal liver metastases were included. In the primary analysis, there was a moderately strong correlation between RFS and OS (\u03c1 = 0.73, 95 per cent c.i. 0.70 to 0.76). The strength of the correlation was similar regardless of the adjuvant treatment regimen (oxaliplatin plus 5-fluorouracil: \u03c1 = 0.72, 0.67 to 0.77; 5-fluorouracil alone: \u03c1 = 0.72, 0.66 to 0.76; observation: \u03c1 = 0.74, 0.69 to 0.78). The mean(s.d.) pairwise correlation coefficient between 3-year RFS and 5-year OS was 0.87(0.06).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In surgically treated patients with colorectal liver metastases, there was a moderately strong correlation between RFS and OS, which was unaffected by the treatment regimen. Further validation using a trial-level analysis is required.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjs\/znad127","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T18:26:50Z","timestamp":1684348010000},"page":"864-869","source":"Crossref","is-referenced-by-count":14,"title":["Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases"],"prefix":"10.1093","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2043-8184","authenticated-orcid":false,"given":"Kozo","family":"Kataoka","sequence":"first","affiliation":[{"name":"Division of Lower Gastrointestinal, Department of Gastroenterological Surgery, Hyogo Medical University , Nishinomiya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Hyogo Medical University , Nishinomiya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-1693","authenticated-orcid":false,"given":"Jiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Hyogo Medical University , Nishinomiya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Lower Gastrointestinal, Department of Gastroenterological Surgery, Hyogo Medical University , Nishinomiya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Beppu","sequence":"additional","affiliation":[{"name":"Division of Lower Gastrointestinal, Department of Gastroenterological Surgery, Hyogo Medical University , Nishinomiya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-4419","authenticated-orcid":false,"given":"Wim","family":"Ceelen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Ghent University Hospital, and Cancer Research Institute Ghent (CRIG), Ghent University , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-3826","authenticated-orcid":false,"given":"Yukihide","family":"Kanemitsu","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, National Cancer Centre Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Ajioka","sequence":"additional","affiliation":[{"name":"Division of Molecular and Diagnostic Pathology, Niigata University, Graduate School of Medical and Dental Sciences , Niigata , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3202-2752","authenticated-orcid":false,"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hepato-Biliary-Pancreatic Surgery Division, Graduate School of Medicine, University of Tokyo , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tokyo Metropolitan Ohkubo Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Division of Lower Gastrointestinal, Department of Gastroenterological Surgery, Hyogo Medical University , Nishinomiya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"2023101313091483900_znad127-B1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/CCO.0b013e32833a6c8a","article-title":"The management of resectable and unresectable liver metastases from colorectal cancer","volume":"22","author":"Kemeny","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"2023101313091483900_znad127-B2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2023101313091483900_znad127-B3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00534-011-0460-z","article-title":"A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a project study for hepatic surgery of the Japanese Society of Hepato-Biliary-Pancreatic surgery","volume":"19","author":"Beppu","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2023101313091483900_znad127-B4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162400","article-title":"Adjuvant oral uracil\u2013tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial","volume":"11","author":"Hasegawa","year":"2016","journal-title":"PLoS One"},{"key":"2023101313091483900_znad127-B5","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.21.01032","article-title":"Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial","volume":"39","author":"Kanemitsu","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023101313091483900_znad127-B6","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2008.17.3781","article-title":"Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials","volume":"26","author":"Mitry","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023101313091483900_znad127-B7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"key":"2023101313091483900_znad127-B8","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2006.06.8353","article-title":"Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial","volume":"24","author":"Portier","year":"2006","journal-title":"J Clin Oncol"},{"key":"2023101313091483900_znad127-B9","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/annonc\/mdp236","article-title":"A randomized phase III study comparing adjuvant 5-fluorouracil\/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer","volume":"20","author":"Ychou","year":"2009","journal-title":"Ann Oncol"},{"key":"2023101313091483900_znad127-B10","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/jnci\/djt269","article-title":"Progression-free survival as a surrogate for overall survival in advanced\/recurrent gastric cancer trials: a meta-analysis","volume":"105","author":"Paoletti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2023101313091483900_znad127-B11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.2014.56.5887","article-title":"Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database","volume":"33","author":"Shi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023101313091483900_znad127-B12","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.ejso.2017.06.017","article-title":"Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: literature-based meta-analysis","volume":"43","author":"Kataoka","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"2023101313091483900_znad127-B13","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","article-title":"Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer","volume":"26","author":"Burzykowski","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023101313091483900_znad127-B14","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1093\/annonc\/mdq204","article-title":"Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?","volume":"21","author":"Soria","year":"2010","journal-title":"Ann Oncol"},{"key":"2023101313091483900_znad127-B15","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1245\/s10434-014-3504-1","article-title":"Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure","volume":"21","author":"Oba","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2023101313091483900_znad127-B16","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S1470-2045(22)00506-X","article-title":"Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis","volume":"23","author":"Ecker","year":"2022","journal-title":"Lancet Oncol"},{"key":"2023101313091483900_znad127-B17","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"2023101313091483900_znad127-B18","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1002\/sim.5874","article-title":"Estimating the correlation of bivariate failure times under censoring","volume":"32","author":"Schemper","year":"2013","journal-title":"Stat Med"},{"key":"2023101313091483900_znad127-B19","year":"2005"},{"key":"2023101313091483900_znad127-B20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2023101313091483900_znad127-B21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/bjs.11609","article-title":"Management of colorectal cancer metastases to the liver, lung or peritoneum suitable for curative intent: summary of NICE guidance","volume":"107","author":"Mohamed","year":"2020","journal-title":"Br J Surg"},{"key":"2023101313091483900_znad127-B22","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1245\/s10434-023-13132-z","article-title":"Practice-changing evidence in surgical oncology 2021: hepatobiliary articles","volume":"30","author":"Wei","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2023101313091483900_znad127-B23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2017.11.014","article-title":"Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review","volume":"123","author":"Savina","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"2023101313091483900_znad127-B24","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s11605-007-0438-y","article-title":"Perioperative morbidity affects long-term survival in patients following liver resection for colorectal metastases","volume":"12","author":"Schiesser","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"2023101313091483900_znad127-B25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/oncolo\/oyac006","article-title":"Surrogacy beyond prognosis: the importance of \u2018trial-level\u2019 surrogacy","volume":"27","author":"Buyse","year":"2022","journal-title":"Oncologist"},{"key":"2023101313091483900_znad127-B26","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1200\/JCO.2007.14.5268","article-title":"Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!","volume":"25","author":"Collette","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023101313091483900_znad127-B27","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.bjc.6602858","article-title":"Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer","volume":"93","author":"Hackshaw","year":"2005","journal-title":"Br J Cancer"},{"key":"2023101313091483900_znad127-B28","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","article-title":"Progression-free survival is a surrogate for survival in advanced colorectal cancer","volume":"25","author":"Buyse","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023101313091483900_znad127-B29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/jnci\/djn515","article-title":"Surrogate and mediating endpoints: current status and future directions","volume":"101","author":"Prentice","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2023101313091483900_znad127-B30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"key":"2023101313091483900_znad127-B31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2017.07.039","article-title":"Multidisciplinary quality assurance and control in oncological trials: perspectives from European Organisation for Research and Treatment of Cancer (EORTC)","volume":"86","year":"2017","journal-title":"Eur J Cancer"},{"key":"2023101313091483900_znad127-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Hashiguchi","year":"2020","journal-title":"Int J Clin Oncol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/110\/7\/864\/52070855\/znad127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/110\/7\/864\/52070855\/znad127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T14:59:44Z","timestamp":1697209184000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/110\/7\/864\/7169397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,5,17]]},"published-print":{"date-parts":[[2023,6,12]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znad127","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,5,17]]}}}